QT as a safety biomarker in drug development

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 1, 2009, Pages 101-104

  Whellan, D J ^a   Green, C L ^b   Piccini, J P ^b   Krucoff, M W ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASTEMIZOLE; CISAPRIDE; GREPAFLOXACIN; LIDOFLAZINE; MOXIFLOXACIN; SERTINDOLE; TERFENADINE; TERODILINE;

AGING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEART PROARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SUDDEN DEATH; T WAVE;

ADULT; AGED; BIOLOGICAL MARKERS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; LONG QT SYNDROME; MALE; YOUNG ADULT;

EID: 67650581733     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.70     Document Type: Review

References (25)

1. Astemizole: voluntary withdrawal: Janssen, USA. WHO Pharmaceuticals Newsletter 1999, nos. 07&08, 18 (UMC, WHO, 1999).
2. Henney, J.E. Withdrawal of troglitazone and cisapride. JAMA 283, 2228 (2000).
3. US Food and Drug Administration. Glaxo Wellcome voluntarily withdraws Raxar (Grepafoxacin) (1999). Accessed 2 March 2009.
4. FDA announces plan to halt marketing of terfenadine. Am. J. Health Syst. Pharm. 54, 342 (1997).
5. Shah, R. Withdrawal of terodiline: a tale of two toxicities. In Pharmacovigilance (eds. Mann, R.D. & Andrews, E.B.) (Wiley, London, 2002).
6. US Food and Drug Administration. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential of Non-Antiarrhythmic Drugs. US Department of Health and Human Services, Food and Drug Administration, Rockville, MD, 2005.
7. Kowey, P.R. & Malik, M. The QT interval as it relates to the safety of non-cardiac drugs. Eur. Heart J. Suppl. 9 (suppl. G), G3-G8 (2007).
8. Mason, J.W., Ramseth, D.J., Chanter, D.O., Moon, T.E., Goodman, D.B. & Mendzelevski, B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J. Electrocardiol. 40, 228-234 (2007).
9. Rautaharju, P.M., Surawicz, B. & Gettes, L.S. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientifc statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 119, e241-e250 (2009).
10. Bazett, H.C. An analysis of the time-relations of electrocardiograms. Heart 7, 35-70 (1920).
11. Fridericia, L.S. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med. Scand. 53, 469-486 (1920).
12. Luo, S., Michler, K., Johnston, P. & Macfarlane, P.W. A comparison of commonly used QT correction formulae: the efect of heart rate on the QTc of normal ECGs. J. Electrocardiol. 37 (suppl.), 81-90 (2004).
13. Franz, M.R., Swerdlow, C.D., Liem, L.B. & Schaefer, J. Cycle length dependence of human action potential duration in vivo. Efects of single extrastimuli, sudden sustained rate acceleration and deceleration, and diferent steady-state frequencies. J. Clin. Invest. 82, 972-979 (1998).
14. Lau, C.P., Freedman, A.R., Fleming, S., Malik, M., Camm, A.J. & Ward, D.E. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc. Res. 22, 67-72 (1988).
15. Smetana, P. , Pueyo, E., Hnatkova, K., Batchvarov, V., Laguna, P. & Malik, M. Individual patterns of dynamic QT/RR relationship in survivors of acute myocardial infarction and their relationship to antiarrhythmic efcacy of amiodarone. J. Cardiovasc. Electrophysiol. 15, 1147-1154 (2004).
16. Malik, M., Hnatkova, K., Schmidt, A. & Smetana, P. Accurately measured and properly heart-rate corrected QTc intervals show little daytime variability. Heart Rhythm 5, 1424-1431 (2008).
17. Statters, D.J., Malik, M., Ward, D.E. & Camm, A.J. QT dispersion: problems of methodology and clinical signifcance. J. Cardiovasc. Electrophysiol. 5, 672-685 (1997).
18. Kligfeld, P. , Tyl, B., Maarek, M. & Maison-Blanche, P. Magnitude, mechanism, and reproducibility of QT interval diferences between superimposed global and individual lead ECG complexes. Ann. Noninvasive Electrocardiol. 12, 145-152 (2007).
19. Roden, D.M. Acquired long QT syndromes and the risk of proarrhythmia. J. Cardiovasc. Electrophysiol. 11, 938-940 (2000).
20. Démolis, J.L., Kubitza, D., Tennezé, L. & Funck-Brentano, C. Efect of a single oral dose of moxifoxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin. Pharmacol. Ther. 68, 658-666 (2000).
21. Morganroth, J. et al. Evaluation of vardenafl and sildenafl on cardiac repolarization. Am. J. Cardiol. 93, 1378-1383, A6 (2004).
22. Bloomfeld, D.M. et al. The efect of moxifoxacin on QTc and implications for the design of thorough QT studies. Clin. Pharmacol. Ther. 84, 475-480 (2008).
23. Bonnemeier, H., Hartmann, F., Wiegand, U.K., Bode, F., Katus, H.A. & Richardt, G. Course and prognostic implications of QT interval and QT interval variability after primary coronary angioplasty in acute myocardial infarction. J. Am. Coll. Cardiol. 37, 44-50 (2001).
24. US Food and Drug Administration. Critical Path Initiative . Accessed 28 February 2009.
25. Cardiac Safety Research Consortium. . Accessed 2 March 2009.